PlainPill

Liraglutide

Also known as Saxenda, Victoza

The short answer. There isn't much data on Liraglutide yet — 15 mentions, 7 with a clear outcome — so treat these numbers as anecdotal. It is most often used for weight loss: 100% of 5 reports say that improved. It is well studied — 418 meta-analyses on PubMed.

What users report
85%helped7 reports · few reports
6 helped0 mixed1 didn't help

From 15 mentions in total — the rest didn't say how it went and aren't counted.

Clinical research
AStrong research base
418
meta-analyses
560
RCTs
5,650
papers
Prescription medication. These are self-reported experiences, not dosing or treatment advice. Prescription drugs have real side effects and interactions — start, stop or change them only with a doctor. Share of positive reports is not a measure of safety.

What Liraglutide does, according to users

Of the people who reported each effect, the share who said it got better.

2 more with fewer than 3 reports
betterno changeworse

What the research says

Systematic reviews and meta-analyses from PubMed, with their published conclusions.

AStrong research base

3+ meta-analyses or systematic reviews and 10+ randomized controlled trials in humans. The grade measures how much human research exists — read the conclusions below for what it found. 418 meta-analyses on PubMed ↗ · 560 randomized trials ↗

Obes Rev · 2025 · Meta-analysis / systematic review
Discontinuing glucagon-like peptide-1 receptor agonists and body habitus: A systematic review and meta-analysis

Conclusion: The proportion of weight regained was proportional to the amount originally lost. Meaning: Discontinuation of GLP-1RA treatment leads to weight regain, regardless of lifestyle interventions, and should therefore be considered a chronic therapy to prevent weight regain and associated undesirable outcomes related to obesity.

PubMed 40186344 ↗
Eur J Clin Pharmacol · 2024 · Meta-analysis / systematic review
The cost-effectiveness analysis of semaglutide for the treatment of adult and adolescent patients with overweight and obesity: a systematic review

Conclusion: The current systematic review showed that semaglutide provides more QALYs and creates more costs in comparison with phentermine-topiramate, phentermine, and naltrexone-bupropion. Semaglutide may be cost-effective with substantial cost reduction. Semaglutide appears to be cost-effective versus diet and exercise (D&E) and liraglutide but it was not cost-effective versus sleeve gastrectomy, endoscopic sleeve gastroplasty, and gastric bypass.

PubMed 39254692 ↗
Registered clinical trials

514 human trials on ClinicalTrials.gov test Liraglutide — 364 completed, 25 recruiting now. See all on ClinicalTrials.gov ↗

What government agencies say

Official records from US, Canadian and EU regulators, each linked to its source.

FDA drug label

Boxed warning (the FDA's strongest label warning): “RISK OF THYROID C-CELL TUMORS Liraglutide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures in both genders of rats and mice. It is unknown whether liraglutide causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in…”

Full label on DailyMed (NIH) ↗

FDA recalls

3 recalls of products named for Liraglutide. Most recent:

  • 2026-05-27 · Class II: Presence of particulate matter: a white thread-like structure in the cartridge record ↗
  • 2021-04-21 · Class II: Temperature Abuse: product samples were stored at temperatures below 32* F which is not in accordance with storage requirements that could cause a lack of… record ↗

Class I = could cause serious harm; Class II = temporary or reversible harm; Class III = unlikely to cause harm. Recalls are of specific products and lots, not of the ingredient itself. All recalls (openFDA) ↗

Reports to the FDA about the drug (FAERS)

49,117 adverse-event reports mention Liraglutide. Most often reported:

  • Nausea · 7,176
  • Blood glucose increased · 3,907
  • Vomiting · 3,515
  • Diarrhoea · 3,376
  • Pancreatitis · 2,329
  • Weight decreased · 2,115

Reports often involve several drugs and serious illness; a report doesn't prove the drug caused the problem, and these counts can't tell you how often it happens. Source query (openFDA) ↗

US government research funding (NIH)

NIH has funded 3 research projects with Liraglutide in the title, $3,300,308 in total (2012–2026). NIH RePORTER ↗

Plain-language guides from the US government: MedlinePlus: Liraglutide Injection ↗

Dosage people report

We don't list doses for prescription medications. Dosing should only come from a doctor or pharmacist.

Reported side effects

How often each side effect came up across all reports.

diarrhea ×1stomach issues ×1gastroparesis ×1pancreatitis ×1

What users say

First-hand experiences, quoted verbatim. We show one positive and one negative where both exist.

Other options for weight loss

Sources

User data from public discussions; research from PubMed. Information only, not medical advice — talk to a doctor before starting, stopping or combining anything. Data updated October 5, 2026. How we rate